Dosage Forms – Page 3 – Talk Bio

Actionable Insights Powered by AI

FDA Approves Ono’s Romvimza for Rare Joint Tumor, Challenging Daiichi Sankyo’s Turalio

10 months ago talkbio0Tagged Approved, CSF1, CSF1 gene, Daiichi, Dosage Forms, Fibrous histiocytoma of tendon sheath, Giant Cell Tumors, Inhibitor, Joint Tumor, Romvimza, Sankyo, tenosynovial, Turalio, United States Food and Drug Administration, Vimseltinib

Romvimza, vimseltinib, tenosynovial giant cell tumor (TGCT), Ono Pharmaceutical, FDA approval, Daiichi Sankyo, Turalio, CSF1 inhibitor, rare joint tumor

FDA Issues Import Alerts for Two Chinese API Manufacturers Following Failed Inspections

11 months ago talkbio0Tagged alpha 1-antitrypsin, Chengdu, Chinese Language, Dosage Forms, Failed, import alert, innovation, Inspection (procedure), manufacturers, Quality, Science of Chemistry, United States Food and Drug Administration, Wuhu

FDA, import alert, Chinese API manufacturers, failed inspections, quality control, Wuhu Nuowei Chemistry, Chengdu Innovation Pharmaceutical

Pharma Ads Make Waves at Super Bowl 2025: Pfizer Wins Hearts, Hims & Hers Drives Engagement

11 months ago talkbio0Tagged Awareness, Dosage Forms, Health care facility, likeability, Malignant Neoplasms, Pfizer, Super Bowl 2025, Viewer Device, Weight-Loss Agents

Super Bowl 2025, pharmaceutical advertising, Pfizer, Hims & Hers, ad likeability, viewer engagement, healthcare marketing, cancer awareness, weight loss drugs

Hims & Hers Super Bowl Ad Sparks Controversy Over Weight Loss Drug Marketing

11 months ago talkbio0Tagged Consumer Safety, Dosage Forms, Glucagon-Like Peptide 1, Hims & Hers, scrutiny, Super Bowl ad, Telemedicine, United States Food and Drug Administration, Weight-Loss Agents

Hims & Hers, Super Bowl ad, weight loss drugs, FDA scrutiny, compounded GLP-1 drugs, pharmaceutical advertising, telehealth, consumer safety

Metsera and Maze Therapeutics Raise $415 Million in Successful Biotech IPOs

11 months ago talkbio0Tagged biotech, Dosage Forms, IPOs, Kidney Diseases, Listings, Metsera, Nasdaq, Obesity

Biotech IPOs, Metsera, Maze Therapeutics, obesity treatment, kidney disease, NASDAQ listings, pharmaceutical funding

Sanofi Acquires Exclusive Rights to Develop and Commercialize Cytokinetics’ Aficamten in Greater China

1 year ago talkbio0Tagged Aficamten, China, Cytokinetics, Dosage Forms, Heart, Hypertrophic Cardiomyopathy, sanofi

Sanofi, Cytokinetics, Aficamten, Greater China, Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitor, Pharmaceutical Deal

FDA Confirms Tirzepatide Availability, Compounders Express Concerns, While Semaglutide Shortage Persists

1 year ago talkbio0Tagged Availability of, Compounders, Dosage Forms, Drug Shortage, Glucagon-Like Peptide 1, semaglutide, United States Food and Drug Administration

FDA, tirzepatide, semaglutide, GLP-1 drug shortage, compounders, pharmaceutical availability

Novo Nordisk Invests $409M in New Quality Control Lab in Denmark

1 year ago talkbio0Tagged Biotechnology, Denmark, Dosage Forms, Nordisk, Quality

Novo Nordisk, quality control lab, Denmark, pharmaceutical investment, biotechnology

GSK Invests $546M in Rgenta’s RNA Modulation Technology for Cancer and Other Diseases

1 year ago talkbio0Tagged Cancer Therapeutic Procedure, Dosage Forms, Investments, Rgenta, RNA modulation, SmithKline Beecham

GSK, Rgenta, RNA modulation, cancer treatment, pharmaceutical investment

Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals for $558.4 Million

1 year ago talkbio0Tagged Biosciences, Coherus, Dosage Forms, immuno-oncology, Intas, pegfilgrastim-cbqv, Udenyca

Coherus BioSciences, Udenyca, Intas Pharmaceuticals, pegfilgrastim-cbqv, immuno-oncology, pharmaceutical deal